Tenderwize
Retour à la recherche

Open-house discount agreement for Sorafenib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 7 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...

Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...

Submission deadline in 7 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house discount agreements for the medicinal product Sorafenib, ATC L01EX02.
  • Supply-related pharmaceutical contract under German social law framework stated by the buyer.
Afficher le résumé complet

This is an open-house supply arrangement for pharmaceutical discount agreements on Sorafenib (ATC L01EX02) by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.11.2024 to 31.10.2026, with contract entry possible until 05.09.2026. Submission can be by handwritten paper originals or by qualified electronic signature via DTVP. No contract value is stated.

Risques

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...

Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...

Submission deadline in 7 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house discount agreement for Sorafenib

Single lot for non-exclusive open-house pharmaceutical discount agreements concerning Sorafenib (ATC L01EX02). The buyer states that identical, non-individually negotiable contracts are offered to all interested pharmaceutical companies meeting the eligibility condition. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 05, 2026

Détails de la procédure

Date de publication
16 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
557828-2024

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30